| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.08. | Xanadu and University of Alberta to develop quantum algorithms for cancer | ||
| 13.08. | United global response to US childhood vaccine overhaul | ||
| 13.08. | Akeso secures China NMPA authorisation for ivonescimab combo | ||
| 13.08. | Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits | ||
| 13.08. | Remepy secures $36m funding for hybrid drug pipeline expansion | ||
| 12.08. | Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli | ||
| 12.08. | Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs | ||
| 12.08. | Epicrispr, Vaderis secure pivotal study funding for rare disease assets | ||
| 12.08. | Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat | ||
| 12.08. | Alfasigma signs agreement to acquire Nordic Group | ||
| 11.08. | Trump signs order that nearly halves childhood immunisation coverage | ||
| 11.08. | UK regulators greenlight Lilly's Foundayo, intensifying Novo competition | ||
| 11.08. | BMS banks on Texas for $2.3bn multi-modal manufacturing facility | ||
| 11.08. | BeOne and Revolution Medicines partner for oncology therapies | ||
| 11.08. | Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront | ||
| 10.08. | Sobi licenses Innate's CTCL drug for up to $580m as it heads to Phase III | ||
| 10.08. | Innovent and Daiichi Sankyo sign deal for Vanflyta in China | ||
| 10.08. | Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs | ||
| 07.08. | Tarsus joins Stargardt race to market with $800m Alkeus takeover | ||
| 07.08. | Context drops bispecific T-cell engager on cost-cutting initiative | ||
| 07.08. | Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations | ||
| 07.08. | Evotec and Odyssey collaborate on AI-enabled R&D | ||
| 07.08. | Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments | ||
| 06.08. | Takeda nets first-in-class advantage on narcolepsy drug's FDA go-ahead | ||
| 06.08. | Eli Lilly raises 2026 outlook again as Q2 soars past estimates |